Ma Q - Search Results

1

Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.

Smith KY, Tierney C, Mollan K, Venuto CS, Budhathoki C, Ma Q, Morse GD, Sax P, Katzenstein D, Godfrey C, Fischl M, Daar ES, Collier AC; AIDS Clinical Trials Group 5202 Study Team. Smith KY, et al. Among authors: ma q. Clin Infect Dis. 2014 Feb;58(4):555-63. doi: 10.1093/cid/cit747. Epub 2013 Nov 18. Clin Infect Dis. 2014. PMID: 24253247 Free PMC article. Clinical Trial.

2

Update on the pharmacokinetic aspects of antiretroviral agents: implications in therapeutic drug monitoring.

Slish JC, Catanzaro LM, Ma Q, Okusanya OO, Demeter L, Albrecht M, Morse GD. Slish JC, et al. Among authors: ma q. Curr Pharm Des. 2006;12(9):1129-45. doi: 10.2174/138161206776055787. Curr Pharm Des. 2006. PMID: 16515491 Review.

3

Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors.

Ma Q, Okusanya OO, Smith PF, Dicenzo R, Slish JC, Catanzaro LM, Forrest A, Morse GD. Ma Q, et al. Expert Opin Drug Metab Toxicol. 2005 Oct;1(3):473-85. doi: 10.1517/17425255.1.3.473. Expert Opin Drug Metab Toxicol. 2005. PMID: 16863456 Review.

4

Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.

Ma Q, Brazeau D, Zingman BS, Reichman RC, Fischl MA, Gripshover BM, Venuto CS, Slish JC, DiFrancesco R, Forrest A, Morse GD. Ma Q, et al. Pharmacogenomics. 2007 Mar;8(3):227-35. doi: 10.2217/14622416.8.3.227. Pharmacogenomics. 2007. PMID: 17324111

5

Drug interactions between proton pump inhibitors and antiretroviral drugs.

McCabe SM, Smith PF, Ma Q, Morse GD. McCabe SM, et al. Among authors: ma q. Expert Opin Drug Metab Toxicol. 2007 Apr;3(2):197-207. doi: 10.1517/17425255.3.2.197. Expert Opin Drug Metab Toxicol. 2007. PMID: 17428151 Review.

6

HIV pharmacotherapy issues, challenges, and priorities in sub-Saharan African countries.

Maponga CC, Ma Q, Slish JC, Morse GD. Maponga CC, et al. Among authors: ma q. Top HIV Med. 2007 Jun-Jul;15(3):104-10. Top HIV Med. 2007. PMID: 17598930 Review.

7

Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.

McCance-Katz EF, Moody DE, Morse GD, Ma Q, DiFrancesco R, Friedland G, Pade P, Rainey PM. McCance-Katz EF, et al. Among authors: ma q. Drug Alcohol Depend. 2007 Dec 1;91(2-3):269-78. doi: 10.1016/j.drugalcdep.2007.06.007. Epub 2007 Jul 23. Drug Alcohol Depend. 2007. PMID: 17643869 Free PMC article.

8

Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.

Slish J, Ma Q, Zingman BS, Reichman RC, Fischl MA, Gripshover B, Forrest A, Brazeau D, Boston NS, Catanzaro L, DiFrancesco R, Morse GD. Slish J, et al. Among authors: ma q. Ther Drug Monit. 2007 Oct;29(5):560-5. doi: 10.1097/FTD.0b013e31806db8ae. Ther Drug Monit. 2007. PMID: 17898644

9

Advances in pharmacogenomics of antiretrovirals: an update.

Ma Q, Brazeau D, Forrest A, Morse GD. Ma Q, et al. Pharmacogenomics. 2007 Sep;8(9):1169-78. doi: 10.2217/14622416.8.9.1169. Pharmacogenomics. 2007. PMID: 17924832 Review.

10

Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir.

Higgins N, Zingman BS, Slish J, Reichman RC, Fischl MA, Gripshover B, Tooley K, Boston N, Forrest A, Brazeau D, Catanzaro LM, DiFrancesco R, Lliguicota F, Ma Q, Morse GD. Higgins N, et al. Among authors: ma q. Am J Addict. 2007 Nov-Dec;16(6):488-94. doi: 10.1080/10550490701641256. Am J Addict. 2007. PMID: 18058416

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10,322 results

Search Page

Filters